Oncotarget

Reviews:

Molecular characterization of circulating tumor cells in lung cancer: moving beyond enumeration

Lei Wang, Coraline Dumenil, Catherine Julié, Violaine Giraud, Jennifer Dumoulin, Sylvie Labrune, Thierry Chinet, Jean-François Emile, Biao He and Etienne Giroux Leprieur _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:109818-109835. https://doi.org/10.18632/oncotarget.22651

Metrics: PDF 1311 views  |   HTML 1858 views  |   ?  


Abstract

Lei Wang1,2, Coraline Dumenil3, Catherine Julié4,5, Violaine Giraud3, Jennifer Dumoulin3, Sylvie Labrune3, Thierry Chinet3,5, Jean-François Emile4,5, Biao He2 and Etienne Giroux Leprieur3,5

1Department of Thoracic Surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

2Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA

3Department of Respiratory Diseases and Thoracic Oncology, APHP – Ambroise Pare Hospital, Boulogne-Billancourt, France

4Department of Pathology, APHP – Ambroise Pare Hospital, Boulogne-Billancourt, France

5EA 4340 “Biomarqueurs en Cancérologie et Onco-Hématologie” UVSQ, Paris-Saclay University, Boulogne-Billancourt, France

Correspondence to:

Etienne Giroux Leprieur, email: [email protected]

Keywords: lung cancer; circulating tumor cells; prognosis; predictive marker; molecular diagnosis

Received: August 05, 2017     Accepted: September 20, 2017     Published: November 23, 2017

ABSTRACT

Molecular characterization of tumor cells is a key step in the diagnosis and optimal treatment of lung cancer. However, analysis of tumor samples, often corresponding to small biopsies, can be difficult and does not accurately reflect tumor heterogeneity. Recent studies have shown that isolation of circulating tumor cells (CTCs) is feasible in non-small cell lung cancer patients, even at early disease stages. The amount of CTCs corresponds to the metastatic potential of the tumor and to patient prognosis. Moreover, molecular analyses, even at the single-cell level, can be performed on CTCs. This review describes the technologies currently available for detecting and capturing CTCs, the potential for downstream molecular diagnostics, and the clinical applications of CTCs isolated from lung cancer patients as screening, prognostic, and predictive tools. Main limitations of CTCs are also discussed.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22651